Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2021 | Reducing therapy-related toxicity in GvHD

Daniel Couriel • 9 Mar 2021
EBMT 2021
General

Daniel Couriel, MD, MS, University of Utah, Salt Lake City, UT, gives a summary of his talk at EBMT 2021 on reducing therapy-related toxicity in graft-versus-host disease (GvHD). Prof. Couriel discusses the challenges of measuring whether toxicity has been successfully reduced in GvHD. Prof. Couriel also talks about the reduced toxicity of novel therapies and the value of non-relapsed mortality as an indirect measure of reduced toxicity. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.

Disclosures

Dr Daniel Couriel, MD, MS, has undertaken consultancy work for Incyte and Fresenius, and has been a non-promotional speaker for Seattle Genetics.

More from Daniel Couriel

3:13
Prednisone with or without ECP for GvHD
Daniel Couriel • 9 Mar 2021

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals